McGill.CA / Cancer Prevention / Publications / Dr. Foulkes' publications

2000 - 2001

On this page:

 Peer-reviewed | Large collaborative studies |Book chapters and reviews | Invited editorials

Peer-reviewed

2001

  1. Bevan S, Pal T, Greenberg CR, Green H, Wixey J, Bignell G, Narod SA, Foulkes WD, Stratton MR and Houlston RS. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, RET, TSHR and TRKA in Familial Non-Medullary Thyroid Cancer: Confirmation of linkage to TCO1. J Clin Endocrinol Metab 86:3701-4, 2001.

  2. Chappuis PO, Hamel N, Paradis A-J, Deschênes J, Robidoux A, Potvin C, Cantin J, Tonin PN, Ghadirian P, Foulkes WD. Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer. Clin Genet 59: 418-423, 2001.

  3. Elhaji YA, Gottleib B, Lumbroso R, Beitel LK, Foulkes WD, Pinsky L and Trifiro M. The Polymorphic CAG Repeat of the Androgen Receptor Gene: A Potential Role in Breast Cancer in Women over 40. Breast Cancer Research and Treatment 70: 109-16, 2001.

  4. Greenblatt MS, Chappuis PO, Bond JP, Hamel N and Foulkes WD. TP53 mutations in BRCA1/2-related breast cancer: distinctive spectrum and structural distribution. Cancer Research 61: 4092-97, 2001.

  5. Jefferies S, Edwards SM, Hamoudi R, A'Hern R, Foulkes W, Goldgar D, MPT collaborators and Eeles R. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. Br J Cancer 85: 1383-6, 2001.

  6. Julian-Reynier C, Bouchard L, Evans DGR, Eisinger F, Foulkes W, Kerr B, Blanquaert, Moatti J-P and Sobol H. Women's attitudes towards preventive strategies for Hereditary Breast/Ovarian cancer risk differ from one country to another: differences between Manchester (UK), Marseilles (F) and Montreal (Ca). Cancer 92:959-68, 2001.

  7. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 38: 784-787, 2001.

  8. Khittoo G, Manning AP, Mustun H, Appadoo J, Venkatasamy S, Fagoonee I Ghadirian P, Tonin PN. Mutation analysis of a Mauritian hereditary breast cancer family reveals the BRCA2 6503delTT mutation previously found to recur in different ethnic populations. Hum Hered 52:55-58, 2001.

  9. Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson A-M, Foulkes WD, Wang T, Morgan K, TM Fujiwara, Tonin PN. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families. Hum Hered 52: 116-120, 2001.

  10. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garver J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Heuhausen SL, Hereditary Ovarian Cancer Clinical Study Group* 2001. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 and BRCA2 mutations: a case control study. Lancet 357:1467-1470. *Tonin PN: Member contributing data.

  11. Pal T, Hamel N, Vesprini D, Sanders K, Mitchell M, Quercia N, Ng Cheong N, Murray A, Foulkes WD and Narod SA. Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. Familial Cancer 1: 17-24, 2001.

  12. Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA and Foulkes WD. Increased risk for non-medullary thyroid cancer (NMTC) in the first-degree relatives of prevalent cases of NMTC: a hospital-based study. J Clin Endocrinol Metab 86: 5307-12, 2001.

  13. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olapade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M-P, Kieback DG, Narod SA. 2001. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11: 1-4.

  14. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risk of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology Biomarkers and Prevention 10: 467-73, 2001.

  15. Thompson D, Easton D, and the Breast Cancer Linkage Consortium*. 2001. Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet. 68:410-419. *Tonin PN: Member contributing data.

  16. Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee P, Novak J, Manderson EN, Provencher D, Mes-Masson A-M. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 20: 6617-6626, 2001.

  17. Tonin PN, Perret C, Lambert J, Paradis A-J, Kantemiroff T, Benoit M-H, Martin B, Foulkes WD, Ghadirian P. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history Int. J Cancer 95: 189-193, 2001.

TOP OF PAGE

2000

  1. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet J-S, Narod SA, Slingerland J and Foulkes WD: Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 18: 4045-4052, 2000.

  2. Dion F, Mes-Masson A-M, Seymour RJ, Provencher D, Tonin PN. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 19: 1466-1472, 2000.

  3. Foulkes WD, Chappuis PO, Wong N, Brunet J-S, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA and Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11: 307-313, 2000.

  4. Hamel N, Black MJ, Ghadirian P and Foulkes WD: No association between p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 82: 757-759, 2000.

  5. Hamel N, Karimi S, Brunet J-S, Gilfix B, Ghadirian P, Black MJ, Narod SA and Foulkes WD: Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco. Int J Cancer 87: 452-454, 2000.

  6. Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J and Narod SA. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes Clin Genet 57: 213-220, 2000.

  7. Liu G, Ghadirian P, Vesprini, D, Hamel N, Paradis A-J, Lal G, Gallinger S, Narod SA and Foulkes WD. Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic cancer. Br J Cancer 82:1646-9, 2000.

  8. Metcalfe K, Liede A, Hoodfar E, Scott A, Foulkes WD and Narod SA: An evaluation of needs among female BRCA1 and BRCA2 mutation carriers undergoing genetic counselling. J Med Genet 37: 866-874, 2000.

  9. Provencher DM, Lounis H , Champoux L, Tetrault M, Manderson E, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson A-M. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol.-Animal 36:357-361, 2000.

  10. Rahman N, Arbour L, Houlston R, Bonaïti-Pellié C, Abidi F, Tranchemontagne J, Ford D, Narod SA, Pritchard-Jones K, Foulkes WD, Schwartz C and Stratton MR. Penetrance of mutations in the familial Wilms tumor gene, FWT1. J Natl Cancer Inst 92: 650-652, 2000.

  11. Rapley E, Barfoot R, Bonaiti-Pellie C, Chompret A, Foulkes W, Perusinghe N, Reeve A, Royer-Pokora B, Schumacher V, Shelling A, Skeen J, de Tourreil S, Weirich A, Pritchard-Jones K, Stratton MR, Rahman N. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. Br J Cancer 83:177-83, 2000.

  12. Wang J-C, Mes-Masson A-M, Tonin PN, Provencher D, Eydoux P. Trisomy of chromosome 10 in two cases of ovarian epithelial carcinoma. Cancer Genet Cytogenet 118: 65-68, 2000.

  13. Yuan ZQ, Chong GL, Thompson-May S, Trifiro M, Khandjian EW, Rousseau F, Yandell D, McNamara E, Gordon PH and Foulkes WD. Analysis of the hMLH1 and hMSH2 genes in three Quebec families with Hereditary Non-Polyposis Colorectal Cancer. Ann Roy Coll Phys Surg Canada 33: 287-291, 2000.

  14. Yen L., You X-L., Al Moustafa A-E., Batist G., Hynes N., Meloche S., and Alaoui-Jamali A.M. 2000. Regulation of Vascular Endothelial Growth Factor Secretion by the ErbB Tyrosine Kinase Receptor Ligand Heregulin in Cancer Cells. Oncogene, 19: 3460-3469.

 TOP OF PAGE

Large collaborative studies

  1. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garver J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Heuhausen SL, Hereditary Ovarian Cancer Clinical Study Group*. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 and BRCA2 mutations: a case control study. Lancet 357:1467-1470, 2001. *Members: Foulkes WD and Tonin PN

  2. Rabelo R, Foulkes W, Gordon PH , Wong N, Yuan ZQ, Chong G, MacNamara E, Pinsky L and Lasko D. Genetic testing in high risk, hereditary colorectal cancer syndromes. Dis Colon Rectum 44: 437-46, 2001.

  3. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olapade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M-P, Kieback DG, Narod SA. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11: 1-4, 2001.

  4. Thompson D, Easton D and the Breast Cancer Linkage Consortium*. Variations in Cancer Risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 68:410-9, 2001. *Members: Foulkes WD, Tonin PN

  5. Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar DE, Hopper J, Bishop DT, Moller P, Heimdal K, Easton D, the CRC/BPG UK Familial Prostate Cancer Study Group, the EU Biomed Collaborators and Simard J. Suggestive evidence for a site-specific prostate cancer gene on chromosome 1p36. J Med Genet 37: 947-949, 2000.

  6. Narod SA, Brunet S-B, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, the Hereditary Breast Cancer Clinical Study Group*. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356: 1876-1881, 2000. * Members: Foulkes WD, Tonin PN

  7. Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnley D, Arden-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Easton DF, Narod SA, Tonin PN and Foulkes WD. High risk genes predisposing to prostate cancer development: do they exist? Prostate Cancer and Prostate Diseases 3, 241-247, 2000.

  8. Xu JF and International Consortium for Prostate Cancer Genetics (ICPCG). Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 66: 945-957, 2000 (Foulkes WD is a member of the ICPCG writing committee for this paper).

TOP OF PAGE

Peer-reviewed and non-peer-reviewed book chapters and reviews

  1. Foulkes WD, Rosenblatt, J and Chappuis PO. The contribution of inherited factors to the development of breast cancer metastases. J Mamm Biol Neoplasia 6: 453-465, 2001.

  2. Jefferies S and Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncology 37: 115-126, 2001.

  3. Wong N, Lasko D, Rabelo R, Pinsky L, Gordon PH and Foulkes W. Genetic counseling and interpretation of genetic tests in hereditary non-polyposis colorectal cancer syndromes. Dis Colon Rectum 44: 271-9, 2001.

  4. Chappuis PO, Ghadirian P and Foulkes WD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: An update. Cancer Invest 19: 63-75, 2001.

  5. Chappuis, PO, Foulkes WD and Provencher, D. Prise en charge du syndrome du cancer du sein et de l'ovaire héréditaire. Deuxième partie: Point de vue de l'oncologue et du gynécologue. Le Clinicien 16: 63-71, 2001.

  6. Chappuis PO, Nethercot V and Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18: 287-295, 2000.

  7. Tonin PN. The genes implicated in hereditary breast cancer syndromes. Semin Surg Oncol 18: 281-286, 2000.

 TOP OF PAGE

Invited editorials

  1. Chappuis PO, Foulkes WD. Commentary on "Prevalence of BRCA1 and BRCA2 mutations in unselected male breast cancer patients in Canada." Clinical Breast Cancer 1: 64-65, 2000.

Back to top